New Prostate Cancer Therapy Shows Early Promise in Trials
Patients with metastatic prostate cancer saw high response rates in a preliminary trial of a new targeted radiation therapy.
Updated on Oct. 23, 2026 in Cancer
Live Poll
Would you consider participating in an experimental clinical trial for a new cancer therapy?
Updated Phase 1 results for the experimental therapy ADVC001 show promising response rates in patients with metastatic prostate cancer. Enrollment is currently underway for Phase 2 trials to further evaluate the safety and effectiveness of this targeted radiopharmaceutical.
Why it matters
Researchers are investigating this therapy to meet unmet needs in advanced prostate cancer treatment. By optimizing dosage strategies, the ongoing trial aims to improve clinical outcomes for those facing this aggressive form of the disease.
This Phase 1 trial evaluated ADVC001 in 22 patients with metastatic prostate cancer over a median follow-up of 14.1 months. Preliminary findings showed an 80 percent PSA50 response rate at 160 and 200 MBq dose levels, with median radiographic progression-free survival reaching 11.2 months.
The players
AdvanCell
A biotechnology company focused on developing targeted alpha therapy radiopharmaceuticals for cancer treatment.
The details
ADVC001 is a PSMA-targeted radiopharmaceutical that delivers a Lead-212 alpha-emitting payload directly to cancer cells. By leveraging a short 10.6-hour half-life, the therapy is designed to deliver localized radiation to tumors while potentially minimizing damage to surrounding healthy tissue. The trial is currently testing dose schedules involving up to 12 cycles to determine how to best prolong clinical benefit.
Timeline
Initial results of the TheraPb study were first reported in 2025.
The data cut-off for the updated trial results was October 5, 2026.
Updated findings were presented at the ESMO Congress in October 2026.
Health Landscape
This research contributes to the expanding field of PSMA-targeted radiopharmaceutical therapy development for advanced prostate cancer. It sits alongside other emerging radionuclide treatments that aim to provide more precise alternatives to traditional systemic chemotherapy.
As this therapy remains in the early stages of clinical testing, it is not yet available for standard clinical practice. Patients managing metastatic prostate cancer should discuss new trial opportunities and emerging targeted treatment options with their oncology care team.
The takeaway
The study demonstrates that targeted alpha therapy could provide a potent new strategy for patients with advanced prostate cancer. Patients interested in novel treatment paths should maintain ongoing conversations with their physicians regarding upcoming clinical trials and their eligibility for experimental studies.
Further reading
For more information on current treatment research, visit Cancer.
Live Poll
Would you consider participating in an experimental clinical trial for a new cancer therapy?
